Conbriza (bazedoxifene) / Pfizer, Ligand, Almirall - LARVOL DELTA

ReWRAP: Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: Riley Bove, MD | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

The PROMISE Study: Duavee in Women With DCIS (clinicaltrials.gov) - P2 | N=142 | Completed | Sponsor: Northwestern University | Recruiting ➔ Completed | Trial primary completion date: Aug 2023 ➔ Jun 2024

Trial completion • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • AGR2 • PTGS2 • UGT1A1

DOMA: Affect of Duavive on Mood & Anxiety Symptoms (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: St. Joseph's Healthcare Hamilton | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2021 ➔ Dec 2025 | Trial primary completion date: Sep 2021 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Detection and occurrence of genetically modified rice and potato in the Saudi food market. (PubMed, Braz J Biol) - "It could be concluded that there were GM rice and potatoes in the Kingdom of Saudi Arabia's food markets. Establishing strong regulations and certified laboratories to monitor genetically modified foods (GMF) or crops in the Saudi market is recommended."

Journal

ReWRAP: Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (clinicaltrials.gov) - P2 | N=62 | Recruiting | Sponsor: Riley Bove, MD | Trial completion date: Aug 2024 ➔ Jun 2025 | Trial primary completion date: Feb 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin combination hormone therapy among women in the United States: a multidatabase cohort study. (PubMed, Menopause) - "CE/BZA users might experience slightly higher rates of endometrial cancer and endometrial hyperplasia, and a lower rate of breast cancer, than EP users in the first years of use."

Journal • Breast Cancer • Cardiovascular • Endometrial Cancer • Oncology • Solid Tumor

ReWRAP: Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Riley Bove, MD | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Feb 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

"zkSync WHITELIST FOR AIRDROP! @Viviant83172743 @babycry66 @AlexGil33 @aneelbhangu @AbuRayh99077999 @spanishjohn420 @melihh101 @JaineBytes @CamilPredescu @SebastianTolka1 @xinyinzhang9 @dtseng123 @nhutho0609 @yavuzyazicii" (@Homelan85703414)

IL33

The PROMISE Study: Duavee in Women With DCIS (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: Northwestern University | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • CD36 • HER-2 • PGR • PTGS2

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR